Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC

by lowes1 on September 20, 2013

Condition:   Non-small Cell Lung Cancer (NSCLC)
Intervention:   Drug: LDK378
Sponsors:   Novartis;   Novartis Pharmaceuticals
Available – verified September 2013

View full post on ClinicalTrials.gov: “Lung Neoplasms” | updated in the last 30 days

Leave a Comment

Previous post:

Next post: